SELECTIVE ESTROGEN RECEPTOR MODULATORS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives the data available in the literature on selective estrogen receptor modulators (SERMs). It considers the mechanism of their action on binding to estrogen receptor, two main (estrogen-agonistic and estrogen-antagonistic) effects, the realization of which depends on the expression of cofactors. The most commonly used SERMs, such as tamoxifen, raloxifene, toremifene, lasofoxifene, and fulvestrant, are described in detail. Their therapeutic effects, adverse reactions, benefits and disbenefits are comparatively shown. It is concluded that the ideal SERM must be effective in treating postmenopausal osteoporosis, have a protective action on breast tissue and beneficial effects on the cardiovascular and central nervous systems, and successfully treat the menopausal syndrome, by causing minimal side effects.

Full Text

Restricted Access

About the authors

M. A OLKHOVSKAYA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of Russia

Email: maria.olkhovskaya@gmail.com

A. A SMETNIK

I.M. Sechenov First Moscow State Medical University

References

  1. Сметник В.П. Медицина климактерия. — М.,Ярославль: Литтерра, 2006. — С. 166—173.
  2. Сметник В.П., Карелина С.Н. Селективные эстроген-рецепторные модуляторы // Руководство по климактерию / Под ред. В.П. Сметник, В.И. Кулакова. — М.: МИА, 2001. — С. 617—625.
  3. Barrett-Connor E., Grady D., Sashegyi A. et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial // J.A.M.A. — 2002. — Vol. 287. — P. 847—857.
  4. Barrett-Connor E., Mosca L., Collins P. et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women // N. Engl. J. Med. — 2006. — Vol. 342. — P. 125—137.
  5. Bryant H. Selective estrogen receptor modulators // Rev. Endocr. Metab. Dis. — 2002. — Vol. 3. — P. 231—241.
  6. Castrellon A.B., Gluck S. Chemoprevention of breast cancer // Expert Rev. Anticancer, Ther. — 2008. — Vol. 8. — P. 443— 452.
  7. Cauley J.A., Norton L., Lippmann M.E. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-years results from the MORE trial. Multiple Outcomes of Reloxifene Evaluation // Breast Cancer Res. Treat. — 2001. — Vol. 65. — P. 125—134.
  8. Cummings S.R., Ensrud K., Delmas P.D. et al. Lazofoxifene in postmenopausal women with osteoporosis // N. Engl. J. Med. — 2010. — Vol. 362. — P. 686—695.
  9. Dede M., Gezginc K., Ulubay M. et al. A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer // Eur. J. Gynecol. Oncol. — 2008. — Vol. 29. — P. 200.
  10. Derman O., Kanbur N.O., Kutluk T. Tamoxifen treatment for pubertal gynecomastia // Int. J. Adolesc. Med. Hlth. — 2003. — Vol. 15. — P. 359—363.
  11. Dhar A., Srivastava A. Role of centchroman in regression of mastalgia and fibroadenoma // World J. Surg. — 2007. — Vol. 31. — P. 1178—1184.
  12. Erdemoglu E., Guney M., Keskin B., Mungan T. Tamoxifen and giant endometrial polyp // Eur. J. Gynecol. Oncol. — 2008. — Vol. 29. — P. 198—199.
  13. Ettinger B., Black D.M., Mitlak B.H. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene // J.A.M.A. — 1999. — Vol. 282. — P. 637—645.
  14. Gielen S.C., Santegoets L.A., Hanifi-Moghaddam P. et al. Signaling by estrogens and tamoxifen in the human endometrium // J. Steroid Biochem. Mol. Biol. — 2008. — Vol. 109. — P. 219—223.
  15. Hall J.M., McDonnell D.P. The estrogen receptor ß-isoform (ERß) of the human estrogen receptor modulates ERa transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens // Endocrinology. — 1999. — Vol. 140. — P. 5566—5578.
  16. Harvey H.A., Kimura M., Hajba A. Toremifene: an evaluation of its safety profile // Breast. — 2006. — Vol. 15. — P. 142—157.
  17. Ishani A., Blackwell T., Jamal S.A. et al. MORE investigators. The effect of raloxifene treatment in postmenopausal women with CKD // J. Am. Soc. Nephrol. — 2008. — Vol. 19. — P. 1430—1438.
  18. Jordan V.C. Selective estrogen receptor modulation: a personal perspective // Cancer Res. — 2001. — Vol. 61. — P. 5683—5687.
  19. Kagan R., Williams R.S. et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women // Maturitas. — 2010. — Vol. 17. — P. 281—289.
  20. Ke H.Z., Foley G.L., Simmons H.A. et al. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats // Endocrinology. — 2004. — Vol. 145. — P. 1996—2005.
  21. Lewiecki F.M. Lasofoxifen for the prevention and treatment of postmenopausal osteoporosis // Ther. Clin. Risk Management. — 2009. — Vol. 5. — P. 817—827.
  22. Li C.P., Lee F.Y., Hwang S.J. et al. Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study // Am. J. Gastroenterol. — 2000. — Vol. 95. — P. 1051—1055.
  23. Lin B.C., Suzawa M., Blind R.D. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation // Cancer Res. — 2009. — Vol. 69. — P. 5415—5423.
  24. Love R.R., Mazess R.B., Barden H.S. et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer // N. Engl. J. Med. 1992. — Vol. 326. — P. 852—856.
  25. Martino S., Disch D., Dowsett S.A. et al. Safety assessment of raloxifene over eight years in a clinical trial setting // Curr. Med. Res. Opin. — 2005. — Vol. 21. — P. 1441—1452.
  26. McClung M., Portman D., Emkey R. et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene //J. Bone Miner. Res. — 2004. — Vol. 19(suppl.). — abstr. SA423.
  27. McDonnell D.P. The molecular pharmacology of SERMs // Trends Endocrinol. Metab. — 1999. — Vol. 10. — P. 301—311.
  28. McKeage K., Curran M.P., Plosker G.L. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy // Drugs. — 2004. — Vol. 64. — P. 633—648.
  29. Nath A., Sitruk-Ware R. Pharmacology and clinical applications of selective estrogen receptor modulators // Climacteric. — 2009. — Vol. 12. — P. 188—205.
  30. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice // N. Engl. J. Med. — 2003. — Vol. 348. — P. 618—629.
  31. Smith C.L., O’Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators // Endocr. Rev. — 2004. — Vol. 25. — P. 45—71.
  32. The Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials // Lancet. —1998. — Vol. 351. — P. 1451—1467.
  33. Tiitenen A., Nikander E., Hietanen P. et al. Changes in bone Nath and Sitruk-Ware mineral density during and after 3 years’ use of tamoxifen or toremifene // Maturitas. — 2004. — Vol. 48. P. 321—327.
  34. Vogel V.G., Constantino J.P., Wickerham D.L. et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial // J.A.M.A. — 2006. — Vol. 295. — P. 2727—2741.
  35. Yaffe K., Krueger K., Cummings S.R. et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial // Am. J. Psychiatry. — 2005. — Vol. 162. — P. 683—690.
  36. Yamamoto Y., Kawazoe T., Iwase H. Experience of highdose toremifene treatment for postmenopausal women with metastatic breast cancer // Gan To Kagaku Ryoho. — 2005. — Vol. 32. — P. 1415—1419.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies